Pacific Biosciences of California Stock Surges 68%, With A 6-Day Winning Spree
Pacific Biosciences of California (PACB) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 68% return. The company has gained about $319 Mil in value over the last 6 days, with its current market capitalization at about $791 Mil. The stock remains 43.7% above its value at the end of 2024. This compares with year-to-date returns of 15% for the S&P 500.
Pacific Biosciences’ recent streak ignited with China’s landmark approval of its Sequel II CNDx system, opening a vast clinical genomics market. This pivotal regulatory win was underscored by Q3’s narrower loss, record consumable revenue, and new SPRQ-Nx chemistry promising sub-$300 genomes, cementing investor confidence.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are several things to fear in PACB stock given its overall Very Weak operating performance and financial condition. In addition, keeping in mind its High valuation, we think that the stock is Very Unattractive (see Buy or Sell PACB).
For quick background, PACB provides advanced sequencing systems and consumables, including SMRT cells and reagent kits, to analyze and resolve genetically complex problems through biochemical sequencing reactions.
Comparing PACB Stock Returns With The S&P 500
The following table summarizes the return for PACB stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | PACB | S&P 500 |
|---|---|---|
| 1D | 5.2% | 0.9% |
| 6D (Current Streak) | 67.5% | 1.4% |
| 1M (21D) | 25.8% | -1.6% |
| 3M (63D) | 97.7% | 4.4% |
| YTD 2025 | 43.7% | 15.0% |
| 2024 | -81.3% | 23.3% |
| 2023 | 19.9% | 24.2% |
| 2022 | -60.0% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 181 S&P constituents with 3 days or more of consecutive gains and 3 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 142 | 1 |
| 4D | 25 | 0 |
| 5D | 6 | 1 |
| 6D | 5 | 0 |
| 7D or more | 3 | 1 |
| Total >=3 D | 181 | 3 |
Key Financials for Pacific Biosciences of California (PACB)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $200.5 Mil | $154.0 Mil |
| Operating Income | $-310.4 Mil | $-290.7 Mil |
| Net Income | $-306.7 Mil | $-309.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $39.8 Mil | $38.4 Mil |
| Operating Income | $-44.9 Mil | $-38.9 Mil |
| Net Income | $-41.9 Mil | $-38.0 Mil |
While PACB stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.